Project: Research project

Project Details


DESCRIPTION: (Applicant's Abstract) Vaccination with antigens that are
expressed in a broad spectrum of histologically distinct unrelated tumor cell
types would be highly desirable. The polypeptide component of telomerase, also
know as telomerase reverse transcriptase or TERT, is an attractive candidate
for a broadly expressed tumor antigen since telomerase is silent in normal
tissues but is reactivated in over 85% of cancers. The primary objective of
this application is to test the hypothesis that telomerase can function as a
broadly useful tumor rejection antigen, namely that vaccination against
telomerase can generate protective immunity against a wide range of unrelated
tumors. The proposed studies will be carried out using murine tumor models. The
specific aims of this application are: 1) to determine whether vaccination
against murine telomerase using dendritic cells transfected with telomerase RNA
will induce CTL and engender protective immunity against histologically
distinct tumors of unrelated origin, 2) to explore the hypothesis and the
mechanism underlying the immunosubdominant nature of telomerase as antigen (see
Preliminary Data section), 3) to explore strategies to augment the antitumor
response elicited by vaccination with telomerase RNA transfected DC. Here the
applicant will test the hypothesis that stimulating a telomerase-specific CD4 T
cell response, T-help, is necessary for generating an optimal anti-telomerase
CTL and anti-tumor immune response and will explore combination therapies to
enhance the anti-telomerase and anti-tumor response generated by vaccination
with telomerase RNA transfected DC. 4) The last specific aim is to evaluate two
additional candidates for broadly expressed tumor rejection antigens: Oncofetal
antigen (OFA) and filamin-1. The long term objective of this project is to
identify several broadly expressed tumor antigens, which in combination will
provide an effective and widely applicable treatment to cancer patients. The
studies proposed in this application will provide the foundations for this
ambitious goal.
Effective start/end date2/1/011/31/06


  • National Cancer Institute: $242,550.00
  • National Cancer Institute: $242,550.00
  • National Cancer Institute: $242,550.00
  • National Cancer Institute: $242,550.00
  • National Cancer Institute: $242,550.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.